View More Recent Stories
-
10x Genomics (TXG) Announces Leadership Changes
-
10X Genomics (TXG) PT Lowered to $32 at Canaccord Genuity
-
Jefferies Upgrades 10X Genomics (TXG) to Buy
-
JPMorgan Downgrades 10X Genomics (TXG) to Neutral
-
10X Genomics (TXG) PT Lowered to $25 at Stifel
-
Life Science Tools & Diagnostics stocks: Q2 earnings preview
-
Deutsche Bank Downgrades 10X Genomics (TXG) to Hold
-
TD Cowen Reiterates Hold Rating on 10X Genomics (TXG)
-
10x Genomics (TXG) Declines After Illumina (ILMN) Acquires Fluent BioSciences
-
Wolfe Research Downgrades 10X Genomics (TXG) to Peerperform
-
10x Genomics (TXG) Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel

